Cover Image
市場調查報告書

全球生物吸收性支架市場

Bioresorbable Scaffolds

出版商 Global Industry Analysts, Inc. 商品編碼 269627
出版日期 內容資訊 英文 126 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生物吸收性支架市場 Bioresorbable Scaffolds
出版日期: 2017年09月01日 內容資訊: 英文 126 Pages
簡介

本報告提供全球生物吸收性支架市場相關調查,彙整市場趨勢與2016∼2024年的預測,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 生物吸收性支架/支架:序論
    • 各種冠狀動脈支架的臨床性特性
    • 生物可再生血管支架:優點與課題
    • 冠狀動脈支架的發展
    • 全球冠狀動脈支架市場
    • 生物吸收性支架
    • 現在及未來分析
    • 發展中國家:成長熱點
  • ABSORB III臨床實驗趨勢:生物可吸收支架產業的變化方面
    • 臨床實驗
    • ABSORB III臨床實驗
    • ABSORB在更小血管的性能
  • 促進成長要素與市場趨勢
    • 冠狀動脈疾病的全球趨勢
    • 高齡化與壽命擴大推動市場成長
    • 中產階級人口增加
    • 高昂的醫療費
    • 肥胖導致CAD的風險提供冠狀動脈支架的前景
    • 糖尿病患者心臟疾病風險較高 其他
  • 開發平台分析
  • 相關法規
    • 美國
    • 歐洲
    • 澳洲
  • 產品概要
  • 近幾年的產業活動
  • 臨床實驗與產品認證
  • 全球主要企業
    • Abbott Laboratories (USA)
    • Amaranth Medical, Inc. (USA)
    • Arterial Remodeling Technologies SA (France)
    • BIOTRONIK SE & Co. KG (Germany)
    • Elixir Medical Corp. (USA)
    • 京都醫療設計
    • REVA Medical, Inc. (USA)
  • 全球市場預測

第3章 市場

  • 美國
  • 歐洲
  • 亞太地區
  • 其他各國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6396

This report analyzes the worldwide markets for Bioresorbable Scaffolds in US$ Thousand. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 17 companies including many key and niche players such as -

Abbott Laboratories
Amaranth Medical, Inc.
Arterial Remodeling Technologies SA
BIOTRONIK SE & Co. KG
Elixir Medical Corp.
Kyoto Medical Planning Co., Ltd.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • BioResorbable Scaffolds/Stents - A Prelude
  • Clinical Characteristics of Various Coronary Stents
  • Bioresorbable Vascular Scaffolds: Advantages and Challenges
  • Evolution of Coronory Stents
  • Global Coronory Stents Market - A Few Key Facts
  • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
  • Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
  • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
  • Challenges in Next-generation BVS Development
    • Desired Features of Bioresorbable Stents
  • Other Available Bioresorbable Scaffolds Exhibit Potential
  • Approved Bioresorbable Scaffolds
  • Magmaris Exhibits Stability and Safety with Lack of Scaffold Thrombosis Occurrence
  • Fantom from REVA Medical
  • DESolve from Elixir Medical
  • ART from Arterial Remodeling Technologies
  • Bioresorbable Scaffolds in Pipeline
  • Current & Future Analysis
  • Developing Countries - Hot Spots for Growth

2. ABSORB III TRIALS - CHANGING THE FACE OF THE BIORESORBABLE STENTS INDUSTRY

  • Absorb Bioresorbable Scaffold/Stent Trials - Adverse Outcomes after Two Years of Placement
  • The ABSORB III Trials
  • Performance of Absorb in Smaller Vessels

3. GROWTH DRIVERS & MARKET TRENDS

  • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
    • Table 1: Global Annual Medical Cost of CVD in the United States: 2015-2030 (includes corresponding Graph/Chart)
    • Table 2: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)
    • Table 3: Top 10 Causes of Death Globally: 2015 (includes corresponding Graph/Chart)
    • Table 4: Top 10 Causes of Death in Low-Income Economies: 2015 (includes corresponding Graph/Chart)
    • Table 5: Top 10 Causes of Death in Lower-Middle-Income Economies: 2015 (includes corresponding Graph/Chart)
    • Table 6: Top 10 Causes of Death in Upper-Middle-Income Economies: 2015 (includes corresponding Graph/Chart)
    • Table 7: Top 10 Causes of Death in High-Income Economies: 2015 (includes corresponding Graph/Chart)
  • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
    • Table 8: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart)
    • Table 9: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
  • Rising Middle Class Population Aids Growth
    • Table 10: Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P (includes corresponding Graph/Chart)
  • Rising Healthcare Expenditure: Opportunities in Store
    • Table 11: Top Countries with the Highest Per Capita Healthcare Spending (2014) (includes corresponding Graph/Chart)
    • Table 12: Healthcare Spending as % of GDP by Geographic Region: 2016 (includes corresponding Graph/Chart)
  • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
    • Table 13: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025 (includes corresponding Graph/Chart)
    • Table 14: Severely Obese Population (in Thousands) Worldwide by Country: 2014 & 2025 (includes corresponding Graph/Chart)
  • Diabetics at Higher Risk of Heart Diseases
    • Table 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)
    • Table 16: Global Prevalence (%) of Diabetes in Adults (20-79) by Region: 2015 & 2040 (includes corresponding Graph/Chart)
    • Table 17: Global Prevalence of Diabetes by Gender (2015 & 2040): Number of Adults Diagnosed with Diabetes (in Million) for Men and Women (includes corresponding Graph/Chart)
    • Table 18: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2015 & 2040 (includes corresponding Graph/Chart)
  • The Hypertension-Cholesterol Link to Drive Demand
    • Table 19: Worldwide Prevalence of Hypertension (BP>=140 OR DBP>=90) (age-standardized estimate) among Male and Female (2014): Breakdown by Select Countries
  • Spurt in Medical Tourism Offers Growth Opportunities
  • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
  • Metal Stents Vis-a-vis Other Stents
  • Alternative Therapies/Devices: Threats to Coronary Stents
  • Cell Transplantation - A Threat to Coronary Stents

4. PIPELINE ANALYSIS

  • Falcon from Abbott
  • Fortitude, Aptitude, and Magnitude from Amaranth
  • Renuvia from Boston Scientific
  • Ideal from Xenogenics
  • MeRes from Meril
  • Mirage from Manli Cardiology
  • Xinsorb from HuaAn Biotechnology
  • Firesorb from MicroPort
  • Unity from QualiMed

5. REGULATORY FRAMEWORK

  • The United States
  • Europe
  • Australia

6. PRODUCT OVERVIEW

  • Coronary Artery Disease (CAD) - A Perspective
  • Causes and Symptoms
  • Treatment Options for Coronary Artery Disease
  • Percutaneous Coronary Intervention (PCI)
  • Coronary Stenting
  • Types of Coronary Stents
    • Bare Metal Stents (BMS)
    • Drug Eluting Stents (DES)
    • Bioresorbable Scaffolds
  • Design and Composition of Bioresorbable Scaffolds
  • Different Types of Bioresorbable Scaffolds
  • Metallic Bioresorbable Scaffolds
  • Polymer Bioresorbable Scaffolds
  • Degradation Period of Select Bioabsorbable Materials
  • Challenges
  • Other Treatment Options for Coronary Heart Disease
  • Coronary Artery Bypass Grafting (CABG)
  • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
  • TransMyocardial Laser Revascularization (TMR)
  • Peripheral Arterial Disease: Understanding the Stealthy Peril
  • Treatment for PAD
    • Lifestyle Changes
    • Medication
    • Surgery
    • Stenting- A Treatment Option for PAD

7. RECENT INDUSTRY ACTIVITY

  • The DGCI Warns Against the Use of Absorb in 2.5 mm or Narrower Blood Vessels
  • Akesys and Elixir Medical Completes Successful Implantation of PRAVA(tm) for Peripheral Vascular Disease
  • Elixir Medical Showcases DESolve CX and AMITY(r) at EuroPCR 2016
  • Micell Technologies Announces Commercialization of MiStent SES(r) in Europe

8. CLINICAL TRIALS AND PRODUCT APPROVALS

  • Elixir Medical Confirms Excellent 5-Year Clinical Data for DESolve(r)
  • Amaranth Medical Announces Nine-month Follow-up RENASCENT-II Study Results of the APTITUDE(r)
  • Abbott's Absorb(tm) Receives Approval as the Japan's First Fully Dissolving Heart Stent
  • Amaranth Medical Initiates Clinical Study for MAGNITUDE(tm) Sirolimus-Eluting Bioresorbable Scaffold
  • Abbott's Absorb(tm) Receives Health Canada Approval
  • BIOTRONIK Obtains CE Mark Approval for Magmaris, the First Magnesium Bioresorbable Scaffold
  • Abbott's Absorb(tm) Receives FDA Approval
  • US FDA Approves Boston Scientific's SYNERGY(tm) BP-DES
  • Abbott Receives CE Mark for Absorb GT1(tm)
  • ART Receives CE Mark Clearance for its Pure Bioresorbable Scaffold

9. FOCUS ON SELECT GLOBAL PLAYERS

  • Abbott Laboratories (USA)
  • Amaranth Medical, Inc. (USA)
  • Arterial Remodeling Technologies SA (France)
  • BIOTRONIK SE & Co. KG (Germany)
  • Elixir Medical Corp. (USA)
  • Kyoto Medical Planning Co., Ltd. (Japan)
  • REVA Medical, Inc. (USA)

10. GLOBAL MARKET PERSPECTIVE

    • Table 20: World Current and Future Analysis for Bioresorbable Scaffolds by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 21: World 9-Year Perspective for Bioresorbable Scaffolds by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2017 and 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Abbott's Decision to End Absorb Sales Brings the US Bioresorbable Scaffolds Market to a Standstill
    • Increasing Incidence of CAD to Drive the Need for More Research into Bioresorbable Stents
    • Rising CVD Incidence - A Major Growth Driver
    • Table 22: Cardiovascular Disease Incidence in the US by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart)
    • Table 23: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)
    • Ageing Population - A Vital Demography
    • Table 24: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Clinical Trials and Product Approvals
    • Strategic Corporate Development
    • Select Key Players
  • B. Market Analytics
    • Table 25: The US Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024

2. EUROPE

  • A. Market Analysis
    • The Largest Market for Bioresorbable Scaffolds Globally
    • Abbott Restricts Availability of Absorb
    • Growth Drivers
    • Cardiovascular Disease in Europe - A Perspective
    • Europe - A Highly Diverse Market
    • Absorbable Stents & the Controversies Surrounding Them
    • Ageing Population Boosts Demand for Biodegradable Stents
    • Table 26: European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
    • Product Approvals
    • Key Players
  • B. Market Analytics
    • Table 27: European Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC

  • A. Market Analysis
    • The Fastest Growing Market for Bioresorbable Scaffolds
    • Growth Drivers
    • Aging Populace - Potential Opportunities
    • Table 28: Over 65 Years Individuals as % of the Total Population in Select Asian Countries (includes corresponding Graph/Chart)
    • Asia-Pacific - A Price Sensitive Market
      • India & China Offer Significant Growth Opportunities
    • Table 29: China and India Lead Global Population (2015): Table Depicting China and India's Huge Population Vis-a-Vis Other Countries' Population (in Millions) by Age Group (includes corresponding Graph/Chart)
    • Focus on Select Markets
      • Australia
      • Abbott Vascular Australia Issues "Hazard Alert" for Absorb BVS
      • India
      • Drug Regulators Issues Warning Regarding Usage of Absorb Stent
      • India Imposes Price Controls on Stents, Boosting Chinese Imports
      • Price Ceiling of Coronary Stents in India
      • India - A Highly Potential Market for CVD Products
      • Unethical Medical Practices Mar Business Prospects
      • Japan
      • Prospects Weighed down by Regulatory Entanglements
      • Bioresorbable Scaffolds Status in Japan
      • China
      • Healthcare Reforms to Propel Stent Market
    • Strategic Corporate Development
    • Kyoto Medical Planning Co., Ltd. (Japan) - A Key Player
  • B. Market Analytics
    • Table 30: Asia-Pacific Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Product Approvals
  • B. Market Analytics
    • Table 31: Rest of World Current and Future Analysis for Bioresorbable Scaffolds Market Analyzed with Annual Sales in US$ Thousands for Years 2016 through 2024 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top